Theravance Biopharma, Inc. - Ordinary Shares (TBPH) News
Filter TBPH News Items
TBPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TBPH News Highlights
- TBPH's 30 day story count now stands at 4.
- Over the past 14 days, the trend for TBPH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO are the most mentioned tickers in articles about TBPH.
Latest TBPH News From Around the Web
Below are the latest news stories about THERAVANCE BIOPHARMA INC that investors may wish to consider to help them evaluate TBPH as an investment opportunity.
7 Short-Squeeze Stocks That Are Screaming for SpeculationWhile the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. |
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of DirectorsTheravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. |
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare ConferenceTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf, CFO, will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA. |
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitableGenerally speaking long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an... |
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Billionaire Seth Klarman’s Biotech Stock PicksIn this article, we discuss billionaire Seth Klarman’s biotech stock picks. To skip the detailed analysis of the biotech industry, Seth Klarman’s investment philosophy, and Baupost Group’s performance and Q3 bets, go directly to Billionaire Seth Klarman’s Top 4 Biotech Stock Picks. Biotechnology is the technology segment that utilizes cellular and biomolecular processes for the […] |
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous SystemTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 34th International Symposium on The Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico. Anchor-based analyses help establish thresholds used to interpret the clinical meaningfulness of ch |
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference Tuesday, November 28 at 1:45 pm EST (10:45 am PST/6:45 pm GMT) and will be hosting in-person meetings with the investment community at the conference. |
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI, a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with COPD. Top-line results showed that YUPELRI met its primary efficacy endpoint demonstrating a statistically sign |
The Consensus EPS Estimates For Theravance Biopharma, Inc. (NASDAQ:TBPH) Just Fell DramaticallyOne thing we could say about the analysts on Theravance Biopharma, Inc. ( NASDAQ:TBPH ) - they aren't optimistic... |